"Lymphocyte Transfusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
| Descriptor ID |
D017710
|
| MeSH Number(s) |
E02.095.135.140.425.445
|
| Concept/Terms |
Lymphocyte Transfusion- Lymphocyte Transfusion
- Lymphocyte Transfusions
- Transfusion, Lymphocyte
- Transfusions, Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "Lymphocyte Transfusion".
Below are MeSH descriptors whose meaning is more specific than "Lymphocyte Transfusion".
This graph shows the total number of publications written about "Lymphocyte Transfusion" by people in this website by year, and whether "Lymphocyte Transfusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphocyte Transfusion" by people in Profiles.
-
Lymphocyte immunotherapy in recurrent miscarriage and recurrent implantation failure. Am J Reprod Immunol. 2021 04; 85(4):e13408.
-
How the COVID-19 pandemic changed cellular therapy at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital. Transfusion. 2020 09; 60(9):1905-1909.
-
Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. Br J Haematol. 2020 08; 190(4):e185-e187.
-
Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date. Br J Haematol. 2020 06; 189(6):1062-1063.
-
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 11; 54(11):1815-1826.
-
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncol. 2018 09 01; 4(9):1245-1253.
-
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Am J Hematol. 2018 03; 93(3):416-423.
-
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. Biol Blood Marrow Transplant. 2018 03; 24(3):627-632.
-
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2070-2078.
-
Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bone Marrow Transplant. 2017 May; 52(5):678-682.